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Edited by Takashi GojoboriAbstract Cytochrome P450 (CYP) 2A6 metabolizes a number
of drugs and a variety of procarcinogens. CYP2A6 also
catalyzes nicotine C-oxidation leading to cotinine formation, a
major metabolic pathway of nicotine in humans. There are
genetic polymorphisms in the human CYP2A6 gene and a
relationship between the CYP2A6 genotype and smoking habits
as well as the incidence of lung cancer has been indicated.
CYP2A6*4 alleles are the whole deleted type and are completely
deﬁcient in the enzymatic activity. An unequal crossover junction
is located in the 30-ﬂanking region in the CYP2A6*4A allele,
whereas the junction is located in either intron 8 or exon 9 in the
CYP2A6*4D allele. In the present study, a novel genotyping
method to distinguish between two diﬀerent whole deleted alleles
of CYP2A6*4A and CYP2A6*4D was established. In the
process, two novel alleles, CYP2A6*1F and CYP2A6*1G, were
found. The CYP2A6*1F has a single nucleotide polymorphism
(SNP) of C5717T in exon 8, and the CYP2A6*1G has two
SNPs, C5717T in exon 8 and A5825G in intron 8. The SNP of
C5717T corresponds to C1224T on the cDNA sequence and is a
synonymous mutation. Since the CYP2A6*1F produces a
recognition site of the restriction enzymes that is the same as
CYP2A6*4D, the presence of the CYP2A6*1F allele could
cause a mistyping as the CYP2A6*4D allele. According to an
improved genotyping method, the allele frequencies of CY-
P2A6*4A, CYP2A6*4D, CYP2A6*1F, and CYP2A6*1G in 165
Caucasians were 3.0%, 0%, 1.8%, and 1.2%, respectively. The
allele frequencies of CYP2A6*4A, CYP2A6*4D, CYP2A6*1F,
and CYP2A6*1G in 94 African-Americans were 0%, 0.5%, 0%,
and 13.3%, respectively. This is the ﬁrst report of a method that
can distinguish between CYP2A6*4A, CYP2A6*4D, and
CYP2A6*1F which could otherwise cause a mistyping as
CYP2A6*4D.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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7-hydroxylation1. Introduction
Cytochrome P450 (CYP) is a superfamily of hemoproteins,
many of which can metabolize xenobiotics such as procarcin-
ogens, drugs, and environmental pollutants. CYP2A6 is a
major hepatic member of the family in humans that metabo-
lizes pharmaceutical agents such as coumarin, methoxyﬂurane,* Corresponding author. Fax: +81-76-234-4407.
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doi:10.1016/j.febslet.2004.05.053halothane, losigamone, letrozole, valproic acid, disulﬁram, and
fadrozole, and activates some procarcinogens such as 4-meth-
ylnitrosoamino-1-(3-pyridyl)-1-butanone and N-nitrosodieth-
ylamine [1]. Especially, CYP2A6 is a major metabolic enzyme
of nicotine. Nicotine is metabolized to cotinine by CYP2A6 [2],
and cotinine is further metabolized to trans-30-hydroxycotinine
by CYP2A6 [3]. In the CYP2A6 gene, several mutated alleles
have been reported. The CYP2A6*1A is a wild type of the
CYP2A6 gene. The CYP2A6*1B allele has a gene conversion
with CYP2A7 in the 30-untranslated region [4]. The CYP2A6*3
allele has gene conversions with CYP2A7 in exons 3, 6, and 8
[5]. CYP2A7 is catalytically inactive. The CYP2A6*2,
CYP2A6*5, CYP2A6*6, CYP2A6*7, CYP2A6*8, and
CYP2A6*11 alleles have single amino acid substitutions of
L160H, G479V, R128Q, I471T, R485L, and S224P, respec-
tively [4,6–9]. The CYP2A6*9 allele has a point mutation in the
TATA box (T-48G) [10]. The CYP2A6*10 allele has two si-
multaneous amino acid substitutions of CYP2A6*7 and
CYP2A6*8 [11,12]. The CYP2A6*4 allele deletes the whole
CYP2A6 gene [13–17]. The CYP2A6*1X2 allele has a dupli-
cation of the CYP2A6 gene [18]. This allele is considered to be
the reciprocal product of the CYP2A6*4 allele after an unequal
crossover event between the 30-ﬂanking regions of the CYP2A6
and CYP2A7 genes. Recently, Oscarson et al. [19] reported a
novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that car-
ries an unequal crossover in intron 2. Kiyotani et al. [20] re-
ported additional alleles possessing a single amino acid
substitution of G5R (CYP2A6*13), S29N (CYP2A6*14),
K194E (CYP2A6*15), and R203S (CYP2A6*16).
In our previous studies [21–25], we investigated the rela-
tionship between the large interindividual diﬀerences in nico-
tine metabolism and the genetic polymorphisms of CYP2A6.
We found that nicotine metabolism is impaired in the homo-
zygotes of either CYP2A6*4, CYP2A6*7 and CYP2A6*10 in
Japanese and Koreans [21–24]. Furthermore, we found that
the CYP2A6*9 allele causes a decrease in nicotine metabolism
[25]. In Caucasians, it has been reported that homozygotes of
the CYP2A6*2 allele were deﬁcient in nicotine metabolism
[26]. Since the CYP2A6*4 allele is a whole deletion type, the
enzymatic activity is completely deﬁcient. There are four types
of CYP2A6*4 alleles, i.e., CYP2A6*4A, CYP2A6*4B, CY-
P2A6*4C, and CYP2A6*4D (Fig. 1). The CYP2A6*4A allele
lacks 30-untranslated region of the CYP2A7 gene and the en-
tire CYP2A6 gene and an unequal crossover junction is located
in the 30-untranslated region [4,13,14]. The CYP2A6*4B allele
lacks the entire CYP2A6 gene, whereas CYP2A7 gene is
normal [17]. The CYP2A6*4C allele is recognized to be the
same as CYP2A6*4A [16]. For the CYP2A6*4D allele, anblished by Elsevier B.V. All rights reserved.
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Fig. 1. Schematic diagram of the various CYP2A6 alleles that have been created through crossover events. Closed and open regions represent
CYP2A7 and CYP2A6 genes, respectively. CYP2A7 is located 25 kb upstream of the CYP2A6 gene.
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9 [15]. Oscarson et al. [15] found one Spanish subject pos-
sessing the CYP2A6*4D allele. However, the allele frequency is
unknown since it was impossible to distinguish between the
CYP2A6*4A or CYP2A6*4D alleles with the PCR method
they used. In the present study, we developed a genotyping
method to distinguish between the CYP2A6*4A and CY-
P2A6*4D alleles. In the process, two novel alleles possessing
synonymous single nucleotide polymorphisms (SNPs) were
found, and one of the alleles could be mistyped as the CY-
P2A6*4D allele. After the improvement of the genotyping
method, the allele frequencies of the CYP2A6*4A, CY-
P2A6*4D, and two novel alleles of CYP2A6*1F and CY-
P2A6*1G in Caucasians and African-Americans were
investigated.2. Materials and methods
2.1. Chemicals and regents
Taq DNA polymerase was obtained from Greiner Japan (Tokyo,
Japan). Restriction enzymes were purchased from Takara (Kyoto,
Japan). Primers were commercially synthesized at Hokkaido System
Sciences (Sapporo, Japan). All other chemicals and solvents were of
the highest grade commercially available.
2.2. Genotyping of the CYP2A6*1A, CYP2A6*1B, CYP2A6*4A, and
CYP2A6*4D alleles
This study was approved by the Human Studies Committee of
Washington University School of Medicine (St. Louis, MO). One-
hundred sixty ﬁve Caucasian (63 male and 102 female) and 94 Af-
rican-American (26 male and 68 female) subjects were recruited.
Written informed consent was obtained from all subjects. Blood
samples were collected from a cubital vein. Genomic DNA was ex-
tracted from peripheral lymphocytes using a Puregene DNA isola-
tion kit (Gentra Systems, Minneapolis, MN). The genotyping of
CYP2A6*1A, CYP2A6*1B, CYP2A6*4A, and CYP2A6*4D was per-
formed as follows: The 2Aex7F (50-GRCCAAGATGCCCTACATG-
30) [15] and 2A6R2 (50-AAAATGGGCATGAACGCCC-30) [15]
primers were used. The 2Aex7F primer could anneal the corre-
sponding region of CYP2A7 as well as that of CYP2A6 The 2A6R2
primer could anneal only CYP2A6. Genomic DNA samples (0.5 lg)
were added to the PCR mixtures (25 ll) consisting of 1 PCR buﬀer
[67 mM Tris–HCl buﬀer (pH 8.8), 16.6 mM (NH4)2SO4, 0.45%
Triton X-100, 0.02% gelatin], 1.5 mM MgCl2, 0.4 lM of each primer,
250 lM dNTPs, and 1 U of Taq DNA polymerase. After an initial
denaturation at 95 C for 1 minute, ampliﬁcation was performed by
denaturation at 95 C for 15 s, annealing at 60 C for 20 s, and
extension at 72 C for 3 min for 35 cycles, followed by a ﬁnal ex-
tension at 72 C for 7 min. The PCR product was double-digested
with Eco81I and AccII restriction enzymes. The digestion patterns
were determined by electrophoresis in a 1.5% agarose gel. Theschematic restriction fragment length polymorphism (RFLP) patterns
are shown in Fig. 2B.
2.3. DNA sequencing
The PCR product with the primers of 2Aex7F and 2A6R2 was
subcloned into pT7Blue T-vector (Novagen, Madison, WI). The
plasmid DNA was puriﬁed by Qiagen Plasmid Midi kit (Qiagen, Va-
lencia, CA) and submitted to DNA sequencing using a Thermo Se-
quenase Cy5.5 Dye Terminator Cycle Sequencing kit (Amersham
Pharmacia Biotech, Buckinghamshire, UK) with T7F primer (Amer-
sham Pharmacia Biotech). DNA sequences were analyzed on a Long-
Read Tower DNA sequencer (Amersham Pharmacia Biotech). To
determine the nucleotide sequences of the novel alleles of CYP2A6*1F
and CYP2A6*1G, DNA sequences of all exons and exon–intron
junctions were analyzed with direct sequence analyses using genomic
DNA from a heterozygote of CYP2A6*1A/CYP2A6*1F and a ho-
mozygote of CYP2A6*1G allele.
2.4. Improved genotyping method for the CYP2A6*1A, CYP2A6*1B,
CYP2A6*4A, CYP2A6*4D, and two novel alleles
To distinguish between the CYP2A6*4D and a novel allele, CY-
P2A6*1F, PCR-RFLP analysis was improved as follows: The
2Aint7F (50-TTTGTGTCAGGAGAATCAAAC-30) and 2A6R2 [15]
primers were used. The 2Aint7F primer could anneal the corre-
sponding region of CYP2A7 as well as that of CYP2A6. Genomic
DNA samples (0.5 lg) were added to the PCR mixtures (25 ll)
consisting of 1 PCR buﬀer, 1.5 mM MgCl2, 0.4 lM of each primer,
250 lM dNTPs, and 1 U of Taq DNA polymerase. After an initial
denaturation at 94 C for 3 min, ampliﬁcation was performed by
denaturation at 94 C for 30 s, annealing at 53 C for 30 s, and
extension at 72 C for 2 min for 30 cycles, followed by a ﬁnal ex-
tension at 72 C for 5 min. The PCR product was triple-digested with
Eco81I, AccII, and StuI restriction enzymes. The digestion patterns
were determined by electrophoresis in a 2% agarose gel. The sche-
matic RFLP patterns are shown in Fig. 3B.
2.5. Distinction between CYP2A6*1A/CYP2A6*4A and CYP2A6*1B/
CYP2A6*4D
In the genotyping method described above, the RFLP pattern of
CYP2A6*1A/CYP2A6*4A and CYP2A6*1B/CYP2A6*4D are the
same. To distinguish between these two genotypes, PCR was per-
formed as follows: The 2Aint7F and 2A6UTR-RV (50-AG-
TCTTAGCTGCGCCCCTC-30) primers were used. The 2A6UTR-RV
primer could speciﬁcally anneal the CYP2A6. Genomic DNA samples
(0.5 lg) were added to the PCR mixtures (25 ll) consisting of 1 PCR
buﬀer, 1.5 mM MgCl2, 0.4 lM of each primer, 250 lM dNTPs, and
1 U of TaqDNA polymerase. After an initial denaturation at 94 C for
3 min, ampliﬁcation was performed by denaturation at 94 C for 20 s,
annealing at 54 C for 20 s, and extension at 72 C for 1.5 min for
35 cycles, followed by a ﬁnal extension at 72 C for 5 min. In the
subjects with CYP2A6*1A/CYP2A6*4A and CYP2A6*1B/CY-
P2A6*4D, the CYP2A6*1A and CYP2A6*4D alleles were expected to
be ampliﬁed, respectively. The PCR product was digested with Eco81I
restriction enzyme. The digestion patterns were determined by elec-
trophoresis in a 2% agarose gel. The schematic RFLP patterns are
shown in Fig. 4B.
Fig. 2. Genotyping of CYP2A6*1A, CYP2A6*1B, CYP2A6*4A, CYP2A6*4D, CYP2A6*1F, and CYP2A6*1G alleles by PCR-RFLP. (A) Schematic
structures of CYP2A7 and CYP2A6 genes. Dotted boxes and open boxes represent exons of CYP2A7 and CYP2A6, respectively. Lines represent
introns of each gene. PCR ampliﬁcation was performed with the primer pairs indicated by horizontal arrows. The ampliﬁed DNA was double-
digested by Eco81I and AccII. The restriction sites of Eco81I and AccII are indicated by vertical arrows of E and A, respectively. (B) Schematic PCR-
RFLP patterns for diﬀerent CYP2A6 alleles. CYP2A6*1A yields 1,316, 427, 120, and 104 bp fragments, CYP2A6*1B yields 1,316, 278, 149, 120, and
104 bp fragments, CYP2A6*4A yields 728, 587, 278, 149, 120, and 104 bp fragments, CYP2A6*4D and CYP2A6*1F yield 728, 587, 427, 120, and 104
bp, and CYP2A6*1G yields 620, 587, 427, 120, 108, and 104 bp fragments.
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The genotypings of CYP2A6*2, CYP2A6*3, CYP2A6*5,
CYP2A6*6, CYP2A6*7, CYP2A6*8, CYP2A6*9, CYP2A6*10,
CYP2A6*11, and CYP2A6*1X2 were also performed as described
previously [11,25]. Genotyping of CYP2A6*12 was carried out ac-
cording to the method by Oscarson et al. [19] with slight modiﬁcations.
Brieﬂy, 2A6ex1 [19] or 2A7ex1 [19] and 2A6ex3R1 [19] primers were
used. Genomic DNA samples (0.5 lg) were added to the PCR mixtures
(25 ll) consisting of 1 PCR buﬀer, 1.5 mM MgCl2, 0.4 lM of each
primer, 250 lM dNTPs, and 1 U of Taq DNA polymerase. After an
initial denaturation at 95 C for 3 min, the ampliﬁcation was per-
formed by denaturation at 95 C for 30 s, annealing at 63 C for 30 s,
and extension at 72 C for 1.5 min for 28 cycles, followed by a ﬁnal
extension at 72 C for 7 min. An aliquot (15 ll) of the PCR product
was analyzed by electrophoresis with 0.8% agarose gel. The CYP2A6*1
allele was ampliﬁed with the primer set of 2A6ex1 and 2A6ex3R1
(1,683 bp) and the CYP2A6*12 allele was ampliﬁed with the primer set
of 2A7ex1 and 2A6ex3R1 (1,598 bp).3. Results
We applied a genotyping method of PCR-RFLP using
primers of 2Aex7F and 2A6R2 to distinguish between theCYP2A6*4A and CYP2A6*4D alleles. As shown in Fig. 2A,
CYP2A6*1A yields 1,316, 427, 120, and 104 bp fragments;
CYP2A6*1B yields 1,316, 278, 149, 120, and 104 bp frag-
ments; CYP2A6*4A yields 728, 587, 278, 149, 120, and 104 bp
fragments; CYP2A6*4D yields 728, 587, 427, 120, and 104 bp
fragments. The schematic RFLP patterns are shown in
Fig. 2B. To conﬁrm the identity of the CYP2A6*4D allele,
DNA sequencing analysis was performed. The PCR product
with the primers of 2Aex7F and 2A6R2 from a subject who
was genotyped as CYP2A6*1A/CYP2A6*4D was subcloned
into pT7Blue T-vector. As the results of the sequencing
analyses, the allele that had been genotyped as CYP2A6*4D
showed the same nucleotide sequence of CYP2A6*1A except
for a SNP of C5717T in exon 8 (Accession No. AC008537, the
A in the initiation codon is nucleotide +1). Therefore, the
allele was not the CYP2A6*4D. The SNP of C5717T corre-
sponds to C1224T on the cDNA sequence and is a synony-
mous mutation. The novel allele was termed CYP2A6*1F. The
SNP of C5717T produces a recognition site of the restriction
enzyme Eco81I. Therefore, the RFLP pattern of the CY-
P2A6*1F allele was the same as that of CYP2A6*4D allele.
Fig. 3. Improved genotyping of CYP2A6*1A, CYP2A6*1B, CYP2A6*4A, CYP2A6*4D, CYP2A6*1F, and CYP2A6*1G alleles by PCR-RFLP.
(A) Schematic structures of CYP2A7 and CYP2A6 genes. Dotted boxes and open boxes represent exons of CYP2A7 and CYP2A6, respectively.
Lines represent introns of each gene. Polymerase chain reaction ampliﬁcation was performed with the primer pairs indicated by horizontal arrows.
The ampliﬁed DNA was triple-digested by Eco81I, AccII, and StuI. The restriction sites are indicated by vertical arrows of E, A, and S, respectively.
(B) Schematic PCR-RFLP patterns for diﬀerent CYP2A6 alleles. CYP2A6*1A yields 1,120, 427, 75, and 29 bp fragments, CYP2A6*1B yields 1,120,
278, 149, 75, and 29 bp fragments, CYP2A6*4A yields 728, 319, 278, 149, 75, 73, and 29 bp fragments, CYP2A6*4D yields 728, 427, 319, 75, 73, and
29 bp, CYP2A6*1F yields 728, 427, 392, 75, and 29 bp, and CYP2A6*1G yields 620, 427, 392, 108, 75, and 29 bp fragments. (C) Representative
photograph of PCR-RFLP patterns for diﬀerent CYP2A6 alleles.
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CYP2A6*4D allele.
In the process of genotyping with the RCR-RFLP method
(Fig. 2), an unexpected 620 bp fragment was observed in
several samples. To conﬁrm the structure of the allele, the PCR
product in which 620 bp fragments was observed was also
subcloned into pT7Blue T-vector, and DNA sequencing
analysis was performed. The allele has two SNPs of C5717T in
exon 8 and A5825G in intron 8 creating the recognition site of
Eco81I and AccII, respectively. The allele was termed CY-
P2A6*1G.
To distinguish between the CYP2A6*4D and CYP2A6*1F
alleles, the PCR-RFLP analysis was improved using the
primers of 2Aint7F and 2A6R2 and triple-digestion with
Eco81I, AccII, and Stu I restriction enzymes. As shown in
Fig. 3B, all genotypes demonstrate diﬀerent RFLP patternsexcept for CYP2A6*1A/CYP2A6*4A and CYP2A6*1B/CY-
P2A6*4D. These two genotypes could be distinguished by
second-step PCR as shown in Fig. 4. The sequences of the
CYP2A6*4D allele genotyped with the improved PCR-
RFLP method were conﬁrmed by DNA sequencing analyses.
Genotyping of all CYP2A6 alleles in 165 Caucasian and 94
African-American subjects was performed. In these subjects,
CYP2A6*1X2,CYP2A6*3,CYP2A6*5,CYP2A6*6,CYP2A6*7,
CYP2A6*8, CYP2A6*10, CYP2A6*11, CYP2A6*12 were not
observed. The allele frequencies of CYP2A6 gene in Caucasians
and African-Americans are summarized in Table 1. The allele
frequencies of CYP2A6*4A were 3.0% and 0.5% in Caucasians
and African-Americans, respectively. The allele frequencies of
CYP2A6*4D were 0% and 0.5% in Caucasians and African-
Americans, respectively. The CYP2A6*1F allele was found in
1.8% of Caucasians. There was a large ethnic diﬀerence in the
Fig. 4. Genotyping of CYP2A6*1A/CYP2A6*4A or CYP2A6*1B/CYP2A6*4D by PCR-RFLP. (A) Schematic structures of CYP2A7 and CYP2A6
genes.Dotted boxes andopen boxes represent exons ofCYP2A7 andCYP2A6, respectively. Lines represent introns of each gene. PCRampliﬁcationwas
performedwith the primer pairs indicated by horizontal arrows.The PCRproducts were digestedbyEco81 I. The restriction sites ofEco81I are indicated
by vertical arrows. (B) Schematic PCR-RFLPpatterns forCYP2A6*1A/CYP2A6*4AorCYP2A6*1B/CYP2A6*4D.CYP2A6*1A yields 1,120, 172, and
104 bp fragments, CYP2A6*4D yields 728, 392, 172, and 104 bp fragments. (C) Representative photograph of PCR-RFLP patterns for CYP2A6*1A/
CYP2A6*4A andCYP2A6*4D allele. In the subjects investigated in our study, therewas no subjectwith theCYP2A6*1B/CYP2A6*4D allele. Therefore,
PCR product for the CYP2A6*4D allele was prepared as follows to conﬁrm the RFLP pattern: the PCR product with the genomic DNA genotyped
CYP2A6*1G/CYP2A6*4D using 2Aint7F and 2A6UTR-RV primers was digested with AccII. The PCR product derived from the CYP2A6*1G allele
was digested to 896 and 500 bp fragments. Non-digested PCR product derived from the CYP2A6*4D allele was prepared from the agarose gel.
Table 1
CYP2A6 genotypes and allele frequencies (%) in 165 Caucasians and 94 African-Americans
Genotype Number of subjects
Caucasians (n ¼ 165) African-Americans (n ¼ 94)
CYP2A6*1A/CYP2A6*1A 55 (33.3) 39 (41.5)
CYP2A6*1A/CYP2A6*1B 49 (29.7) 18 (19.1)
CYP2A6*1A/CYP2A6*1F 3 (1.8) 0 (0)
CYP2A6*1A/CYP2A6*1G 0 (0) 17 (18.1)
CYP2A6*1B/CYP2A6*1B 15 (9.1) 0 (0)
CYP2A6*1B/CYP2A6*1F 3 (1.8) 0 (0)
CYP2A6*1B/CYP2A6*1G 0 (0) 1 (1.1)
CYP2A6*1G/CYP2A6*1G 2 (1.2) 2 (2.1)
CYP2A6*1A/CYP2A6*2 2 (1.2) 0 (0)
CYP2A6*1A/CYP2A6*4A 9 (5.5) 1 (1.1)
CYP2A6*1B/CYP2A6*4A 1 (0.6) 0 (0)
CYP2A6*1G/CYP2A6*4D 0 (0) 1 (1.1)
CYP2A6*1A/CYP2A6*9 16 (9.7) 11 (11.7)
CYP2A6*1B/CYP2A6*9 8 (4.8) 2 (2.1)
CYP2A6*1G/CYP2A6*9 0 (0) 2 (2.1)
CYP2A6*2/CYP2A6*9 2 (1.2) 0 (0)
Allele Number of alleles
Caucasians (n ¼ 330) African-Americans (n ¼ 188)
CYP2A6*1A 189 (57.3) 125 (66.5)
CYP2A6*1B 91 (27.6) 21 (11.2)
CYP2A6*1F 6 (1.8) 0 (0)
CYP2A6*1G 4 (1.2) 25 (13.3)
CYP2A6*2 4 (1.2) 0 (0)
CYP2A6*4A 10 (3.0) 1 (0.5)
CYP2A6*4D 0 (0) 1 (0.5)
CYP2A6*9 26 (7.9) 15 (8.0)
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and African-Americans (13.3%). The allele frequencies of
CYP2A6*2 andCYP2A6*9were consistent with previous reports
[10,15,18].4. Discussion
Both CYP2A6*4A and CYP2A6*4D are deleted alleles of
the CYP2A6 gene. An unequal crossover junction is located
in the 30-ﬂanking region in the CYP2A6*4A allele, whereas
the junction is located in either intron 8 or exon 9 in the
CYP2A6*4D allele [15]. With the previous two-step PCR
method using 2A7ex8F and 2A6R2 primers [15], it was
impossible to distinguish the CYP2A6*4D allele from the
CYP2A6*4A allele. In the present study, we developed a
PCR-RFLP method for distinguishing between the CY-
P2A6*4A and CYP2A6*4D alleles. In the process of geno-
typing, two novel alleles of CYP2A6*1F and CYP2A6*1G
were found. These alleles have a synonymous SNP of C5717T
in exon 8. It is considered that the enzymatic activities of
these alleles might be similar to those of the wild-type, which
should be conﬁrmed in the near future. Since the CY-
P2A6*1F allele demonstrated the same RFLP pattern of
CYP2A6*4D, it would cause a mistyping. The improved
genotyping method developed in the present study makes
it possible to distinguish between the CYP2A6*4A, CY-
P2A6*4D and CYP2A6*1F alleles.
In the results of the genotyping of 165 Caucasians, the allele
frequencies of CYP2A6*4A and CYP2A6*4D were 3.0% and
0%, respectively. In 94 African-Americans, the allele frequen-
cies of CYP2A6*4A and CYP2A6*4D were both 0.5%. This is
the ﬁrst study to report separately the allele frequencies of the
CYP2A6*4A and CYP2A6*4D alleles. Furthermore, we con-
ﬁrmed that the subjects genotyped with CYP2A6*4 in Japa-
nese and Koreans in our previous studies [22,23] were all
CYP2A6*4A using the novel method established in the present
study. Thus, the CYP2A6*4D allele was not found and the
allele frequencies of CYP2A6*4A in Japanese and Koreans
were 20.1% and 11.0%, respectively [22,23]. It has been re-
ported that the allele frequency of CYP2A6*4 is 1.0% in Finns
[15], 0.5% in Spaniards [15], 15.1% in Chinese [15], and 1.18%
in Caucasians [18]. With the PCR-RFLP method established in
the present study, it will be possible to know the exact allele
frequencies of CYP2A6*4A and CYP2A6*4D in these
populations.
In our previous studies, the eﬀects of genetic polymorphisms
of the human CYP2A6 gene on in vivo nicotine metabolism
were conﬁrmed [11,21–25,27]. Furthermore, a relationship
between the CYP2A6 genotype and smoking habits [18,28] as
well as the incidence of lung cancer [29] has been indicated.
Since CYP2A6 can metabolize pharmaceutical agents, the
genetic polymorphism of the CYP2A6 gene would be clinically
important in so far as certain drugs are speciﬁcally metabolized
by CYP2A6.
In conclusion, we developed a new genotyping method for
distinguishing between two diﬀerent whole deleted alleles,
CYP2A6*4A and CYP2A6*4D as well as novel CYP2A6*1F
and CYP2A6*1G alleles. Since the enzymatic activities of
CYP2A6*4D and CYP2A6*1F are considered to be diﬀerent,
the mis-genotyping would show an apparent inconsistency
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